Progyny Inc (NAS:PGNY)

$ 26.95 0.33 (1.24%) Market Cap: 2.57 Bil Enterprise Value: 2.21 Bil PE Ratio: 44.18 PB Ratio: 4.53 GF Score: 85/100

Q4 2023 Progyny Inc Earnings Call Transcript
Feb 27, 2024

$40.79 (+2.31%)

Earnings
Progyny Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Q3 2023 Progyny Inc Earnings Call Transcript
Nov 07, 2023

$32 (+3.80%)

Earnings
Q2 2023 Progyny Inc Earnings Call Transcript
Aug 03, 2023

$40.43 (-1.15%)

Earnings
Progyny Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Progyny Inc Annual Shareholders Meeting Transcript
May 24, 2023
Progyny Inc at Bank of America Global Healthcare Conference Transcript
May 09, 2023
Q1 2023 Progyny Inc Earnings Call Transcript
May 08, 2023

$34.85 (+0.78%)

Earnings
Q4 2022 Progyny Inc Earnings Call Transcript
Feb 27, 2023

$31.09 (+1.70%)

Earnings
Progyny Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Progyny Inc at Credit Suisse Healthcare Conference Transcript
Nov 09, 2022
Q3 2022 Progyny Inc Earnings Call Transcript
Nov 03, 2022

$38.92 (-3.28%)

Earnings
Progyny Inc at Bank of America Merrill Lynch Global Healthcare Conference Transcript
Sep 15, 2022
Q2 2022 Progyny Inc Earnings Call Transcript
Aug 04, 2022

$29.77 (-8.54%)

Earnings
Progyny Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2022
Progyny Inc Annual Shareholders Meeting Transcript
May 25, 2022
Progyny Inc at Bank of America Healthcare Conference Transcript
May 11, 2022
Q1 2022 Progyny Inc Earnings Call Transcript
May 05, 2022

$36.82 (-8.27%)

Earnings
Progyny Inc at Barclays Global Healthcare Conference Transcript
Mar 15, 2022
Q4 2021 Progyny Inc Earnings Call Transcript
Feb 28, 2022

$39.36 (+1.76%)

Earnings
Progyny Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Q3 2021 Progyny Inc Earnings Call Transcript
Nov 04, 2021

$60.28 (-1.74%)

Earnings
Progyny Inc at Bank of America Global Healthcare Conference (Virtual) Transcript
Sep 15, 2021
Progyny Inc at Bank of America SMID Cap Ideas Conference (Virtual) Transcript
Aug 10, 2021
Q2 2021 Progyny Inc Earnings Call Transcript
Aug 05, 2021

$55.36 (-0.02%)

Earnings
Progyny Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021
Progyny Inc Annual Shareholders Meeting Transcript
Jun 02, 2021
Progyny Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 12, 2021
Q1 2021 Progyny Inc Earnings Call Transcript
May 06, 2021

$52.1 (-2.45%)

Earnings
Q4 2020 Progyny Inc Earnings Call Transcript
Feb 24, 2021

$53.34 (+4.02%)

Earnings
Progyny Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021
Q3 2020 Progyny Inc Earnings Call Transcript
Nov 05, 2020

$27.35 (+0.92%)

Earnings
Progyny Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Q2 2020 Progyny Inc Earnings Call Transcript
Aug 05, 2020

$27.56 (+1.40%)

Earnings
Progyny Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2020
Progyny Inc Annual Shareholders Meeting Transcript
Jun 02, 2020
Progyny Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020
Q1 2020 Progyny Inc Earnings Call Transcript
May 12, 2020

$20.49 (-4.48%)

Earnings
Q4 2019 Progyny Inc Earnings Call Transcript
Mar 05, 2020

$27.43 (-4.52%)

Earnings
Progyny Inc at JPMorgan Healthcare Conference Transcript
Jan 13, 2020
Q3 2019 Progyny Inc Earnings Call Transcript
Dec 04, 2019

$26.34 (-4.98%)

Earnings

Q1 2022 Progyny Inc Earnings Call Transcript

May 05, 2022 / 08:45PM GMT

Release Date Price: $36.82 (-8.27%)

Transcript 10-Q8-K

Operator

Good day, ladies and gentlemen, and welcome to the Progyny, Inc. First Quarter 2022 Earnings Conference Call. (Operator Instructions)

It is now my pleasure to turn the floor over to your host, James Hart, Vice President of Investor Relations. James, the floor is yours.

James Hart

Progyny, Inc. - VP of IR

Thank you, Paul, and good afternoon, everyone. Welcome to our first quarter conference call. With me today are Peter Anevski, CEO of Progyny; Michael Sturmer, President; and Mark Livingston, CFO. We will begin with some prepared remarks before we open the call for your questions.

Before we begin, I'd like to remind you that today's call contains forward-looking statements, including, but not limited to, statements about our financial outlook for both the second quarter and the full year of 2022, including our expected utilization rate and mix; the impact of COVID-19 including variance on our business, clients, member activity and industry operations; our ability to acquire new clients and retain and upsell existing clients; our market

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.